GleamWall
中文EN

CPMD CANNAPHARMARX, INC.

Pharmaceutical Preparations · OTC · SEC CIK 1081938 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-30.8%
TTM net income YoY-25.6%
TTM EPS YoY50.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin-114.1%
Operating margin-210.8%
Net margin-779.2%
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-97.3%
ROIC (approx.)—
Asset turnover0.12x

Leverage & solvency

Liabilities / assets514.2%
Debt / equity—
Current ratio0.05x
Interest coverage-1.70x

Cash quality & payout

Operating cash flow / net income-0.06x
Accruals ratio-102.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$137,705$276,218$627,462$138,630$656,606$231,608$335,319$482,134
Cost of revenue$415,487$414,664$1.04M$659,721$1.03M$852,818$837,926$2.17M
Gross profit-$277,782-$138,446-$409,453-$521,091-$373,707-$621,210-$502,607-$1.69M
SG&A expense$159,445$82,739$35,814$229,604$211,737$75,952$38,641-$128,897
Operating income-$532,943-$378,831-$682,343-$893,553-$935,646-$840,980-$677,585-$1.53M
Interest expense$458,291$349,008$475,617$179,423$506,331$657,515$615,516$322,210
Pretax income$645,416-$1.91M——-$1.48M-$1.41M——
Income tax$0$0—$0$0$0——
Net income$645,416-$1.91M-$382,021-$7.55M-$1.48M-$1.41M-$690,594-$3.74M
EBITDA-$513,497-$360,359-$666,535—-$935,646-$840,980-$659,076-$1.62M
EPS (basic)0.000.00——0.000.00——
EPS (diluted)0.000.000.00—0.000.000.00—
Weighted avg. shares (diluted)1.27B682.48M669.79M—662.50M662.50M662.50M—
Balance sheet
Cash & equivalents$32,037$555$633$1,804$927$16,975$1,208$2,156
Receivables$0$6,811$6,944$164,430———$1,747
Inventory$1.70M$1.31M$902,913$1.12M$863,807$1.04M$951,136$996,250
Current assets$1.74M$1.33M$929,554$1.31M$1.47M$1.20M$1.24M$1.02M
PP&E, net$194,651$200,461$176,101$127,029$123,333$129,389$130,077$137,237
Total assets$7.29M$6.89M$6.58M$7.02M$11.62M$11.47M$11.23M$10.84M
Current liabilities$32.67M$32.57M$31.49M$31.59M$28.48M$28.95M$26.89M$25.75M
Total liabilities$37.47M$37.72M$36.85M$37.17M$34.13M$34.05M$31.74M$30.65M
Shareholders' equity-$30.19M-$30.83M-$30.27M-$30.15M-$22.52M-$22.57M-$20.51M-$19.81M
Shares outstanding708.69M708.69M678.50M662.50M662.50M662.50M662.50M662.50M
Cash flow statement
Operating cash flow-$166,650-$127,369-$243,656$1.06M-$802,700-$446,463-$601,381-$179,890
Capital expenditure$588——$5,519$0——$0
Free cash flow-$167,238——$1.06M-$802,700——-$179,890
Investing cash flow-$588——$794,269$0——$0
Financing cash flow$199,175$182,409$242,485-$1.85M$786,652$462,230$600,433$175,047
Depreciation & amortization$19,446$18,472$15,808—$0$0$18,509-$87,278

Free plan shows the latest 8 periods; Pro shows all 67 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.